Discontinued — last reported Q3 '24
Zyprexa — Revenue
Eli Lilly Zyprexa — Revenue decreased by 97.9% to $31.70M in Q3 2024 compared to the prior quarter. Year-over-year, this metric declined by 97.9%, from $1.48B to $31.70M. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase suggests sustained market demand or successful lifecycle management, while a decrease indicates potential loss of patent exclusivity, increased generic competition, or a shift in clinical prescribing patterns.
Detailed definition
This metric represents the total net sales generated from the Zyprexa product line, an antipsychotic medication used in...
Peer comparison
Comparable to revenue metrics for legacy or off-patent pharmaceutical products at other large-cap drug manufacturers, often evaluated against generic erosion curves.
lly_segment_zyprexa_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q3 '23 | Q3 '24 | |
|---|---|---|---|---|---|---|---|---|---|
| Value | $95.40M | $101.70M | $137.40M | $93.10M | $87.30M | $81.40M | $75.10M | $1.48B | $31.70M |
| QoQ Change | — | +6.6% | +35.1% | -32.2% | -6.2% | -6.8% | -7.7% | >999% | -97.9% |
| YoY Change | — | — | — | — | -8.5% | -20.0% | -45.3% | >999% | -97.9% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Eli Lilly's zyprexa — revenue?
- Eli Lilly (LLY) reported zyprexa — revenue of $31.70M in Q3 2024.
- How has Eli Lilly's zyprexa — revenue changed year-over-year?
- Eli Lilly's zyprexa — revenue decreased by 97.9% year-over-year, from $1.48B to $31.70M.
- What does zyprexa — revenue mean?
- The total revenue generated from the sales of the antipsychotic drug Zyprexa.